Trial of NovoSeven® in Haemophilia - Joint Bleeds
| Status: | Completed |
|---|---|
| Conditions: | Hematology, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | Any - 20 |
| Updated: | 1/13/2017 |
| Start Date: | September 2001 |
| End Date: | February 2006 |
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
This trial is conducted in the United States of America (USA). This study compares the
effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with
inhibitors being treated for joint bleeds.
effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with
inhibitors being treated for joint bleeds.
Inclusion Criteria:
- Diagnosis of hemophilia A or B with inhibitors to factor VIII or IX, respectively
We found this trial at
19
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials